Discover undervalued stocks with Eulerpool.

Subscribe for $2

Precigen Stock PGEN

Price

0
Today +/-
-0
Today %
-0 %

Precigen stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Precigen stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Precigen stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Precigen stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Precigen's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Precigen Stock Price History

DatePrecigen Price
10/7/20250 undefined
10/7/20253.19 undefined
10/6/20253.18 undefined
10/3/20253.24 undefined
10/3/20253.26 undefined
10/2/20253.34 undefined
10/1/20253.37 undefined
9/29/20253.29 undefined
9/28/20253.63 undefined
9/25/20253.51 undefined
9/24/20253.49 undefined
9/24/20253.86 undefined
9/24/20253.93 undefined
9/23/20253.71 undefined
9/22/20253.91 undefined
9/19/20253.76 undefined
9/19/20253.77 undefined
9/18/20253.82 undefined
9/17/20253.84 undefined
9/16/20253.96 undefined
9/15/20253.60 undefined
9/12/20253.79 undefined
9/12/20253.82 undefined
9/11/20254.16 undefined
9/10/20254.02 undefined
9/9/20254.15 undefined
9/8/20254.13 undefined

Precigen Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Precigen, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Precigen from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Precigen’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Precigen. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Precigen’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Precigen’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Precigen’s growth potential.

Precigen Revenue, EBIT and net profit per share

DatePrecigen RevenuePrecigen EBITPrecigen Net Income
2030e618.23 M undefined0 undefined215.73 M undefined
2029e523.21 M undefined302.58 M undefined204.81 M undefined
2028e413.89 M undefined216.52 M undefined163.85 M undefined
2027e280.92 M undefined109.92 M undefined80.56 M undefined
2026e110.99 M undefined-30.35 M undefined-192.98 M undefined
2025e13.7 M undefined-103.82 M undefined-109.23 M undefined
20243.93 M undefined-94.71 M undefined-126.24 M undefined
20236.23 M undefined-88.92 M undefined-95.9 M undefined
202226.9 M undefined-74.6 M undefined28.3 M undefined
202114.3 M undefined-91.4 M undefined-92.2 M undefined
2020103.2 M undefined-85.7 M undefined-170.5 M undefined
201990.7 M undefined-136 M undefined-322.3 M undefined
2018151.2 M undefined-369.7 M undefined-509.3 M undefined
2017219.5 M undefined-82.1 M undefined-117 M undefined
2016190.9 M undefined-125.2 M undefined-186.6 M undefined
2015173.6 M undefined-146.9 M undefined-84.5 M undefined
201471.9 M undefined-70 M undefined-81.8 M undefined
201323.8 M undefined-58 M undefined-57.4 M undefined
201213.8 M undefined-75.2 M undefined-103.9 M undefined
20118.2 M undefined-82.4 M undefined-99.1 M undefined

Precigen Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (M)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
201120122013201420152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
81323711731902191519010314266313110280413523618
-62.5076.92208.70143.669.8315.26-31.05-40.4014.44-86.4185.71-76.92-50.00333.33746.15154.5547.5026.6318.16
250.00100.00100.0088.7363.0167.8971.6958.2832.2245.6357.1476.92333.33666.67153.8518.187.144.843.823.24
013236310912915788294782000000000
-99-103-57-81-84-186-117-509-322-170-9228-95-126-109-19280163204215
-4.04-44.6642.113.70121.43-37.10335.04-36.74-47.20-45.88-130.43-439.2932.63-13.4976.15-141.67103.7525.155.39
5.25.54199.2111.1118120129.5154.1167.1197.8200.4244.54267.73000000
- - - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Precigen Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Precigen is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (M)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (M)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (M)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (B)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (k)
EQUITY (M)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (M)
20112012201320142015201620172018201920202021202220232024
                           
19.910.7177.5116238.3237.279.7216.975.1100.1108.75662.8697.91
0.30.76.127.248.738.437.725.321.316.51.410.90.93
101.32.13.64.12.11.34.93.90.612.80.670.24
00025.826.621.120.520.616.111.40.30.300
1.82.22.73.86.614.414.121.4117.217.145.748.14.333.34
2313.6187.6174.9323.8315.2154.1285.5234.6149156.7118.268.76102.41
18.518.716.63842.764.7112.786.986.244.318.615.414.2118.89
39.188.8208.4195.2199.1182.7189.92.81.5048.6000
00000000000000
32.529.54265.9247.5225.6232.98968.365.452.344.540.74.46
0013.8101.1165.2157.2153.393.663.854.437.636.926.6119.14
1.71.11.11.33.73.74.1158.41.41.646.210.770.37
91.8138.1281.9401.5658.2633.9692.9430.7221.2165.7203.397.882.2942.85
114.8151.7469.5576.4982949.1847716.2455.8314.7360216151.04145.27
                           
301.7406.70000000000028.22
000.740.841.251.331.41.721.751.892.0222.082.13
-221.3-321.6-376.4-458.2-542.7-729.3-847.8-1,330.5-1,652.9-1,823.4-1,915.6-1,868.6-1,964.47-2,090.71
000.10-12.8-36.2-15.6-28.6-27.540.5-2.7-1.910
0000000-10000-300-800-3312
80.485.1366.8384.8694.1560.3533.6362.871.667.2107.3126.2118.566.73
3.10.61.16.358.58.7125.94.63.14.11.733.53
5.369.313.52722.327.62930.320.317.131.320.7517.4
9.110.19.423.842.462.643.219.753.116.914.400.510.59
0002.30.60.80.20.51.900000
0.1001.70.90.40.50.531.70.40.143.200
17.616.719.847.675.994.680.261.7122.942.234.778.622.9921.52
0.101.78.77.67.67.5211.2186.3171.5179.9000
000021.81715.63.92.82.92.52.31.850
16.749.866.6110.8171.9260.619760.87230.935.48.87.7157.02
16.849.868.3119.5201.3285.2220.1275.9261.1205.3217.811.19.5657.02
34.466.588.1167.1277.2379.8300.3337.6384247.5252.589.732.5578.54
114.8151.6454.9551.9971.3940.1833.9700.4455.6314.7359.8215.9151.04145.27
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Precigen provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Precigen's financial health and stability.

Assets

Precigen's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Precigen must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Precigen after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Precigen's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (k)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (k)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
2011201220132014201520162017201820192020202120222023
-85-81-40-85-87-190-126-514-323-170-9228-95
4771017243133241713106
00001,000-3,000-2,000-21,000-3,0000000
-42-81258-10-74-192-200-223
411-86514618312143418211537-7129
0000100337781
00001,00000000000
-81-61-53-1935-48-103-124-135-77-55-65-66
-13-7-1-6-12-38-60-41-37-7-7-4-1
-64-23-223-26-259-28104-1518627-74226-3
-51-16-222-19-24610165-10912435-67231-1
0000000000000
140169-2-3002191-20-154-43
1287615026342191490635121072
1487531624331124309832121-15529
40-30-7-6-9000000
0000000000000
2-939-22108-66534-41-16-85-40
-94.76-69.02-55.21-26.2322.92-87.86-164.61-165.83-173.81-84.55-63.02-69.97-68.47
0000000000000

Precigen stock margins

The Precigen margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Precigen. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Precigen.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Precigen's sales revenue. A higher gross margin percentage indicates that the Precigen retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Precigen's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Precigen's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Precigen's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Precigen. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Precigen's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Precigen Margin History

Precigen Gross marginPrecigen Profit marginPrecigen EBIT marginPrecigen Profit margin
2030e-8.71 %0 %34.9 %
2029e-8.71 %57.83 %39.15 %
2028e-8.71 %52.31 %39.59 %
2027e-8.71 %39.13 %28.68 %
2026e-8.71 %-27.35 %-173.87 %
2025e-8.71 %-757.69 %-797.2 %
2024-8.71 %-2,412.87 %-3,216.18 %
20231.7 %-1,428.48 %-1,540.63 %
202276.58 %-277.32 %105.2 %
202159.44 %-639.16 %-644.76 %
202046.22 %-83.04 %-165.21 %
201932.3 %-149.94 %-355.35 %
201858.53 %-244.51 %-336.84 %
201771.89 %-37.4 %-53.3 %
201667.73 %-65.58 %-97.75 %
201563.19 %-84.62 %-48.68 %
201488.6 %-97.36 %-113.77 %
201399.58 %-243.7 %-241.18 %
2012100 %-544.93 %-752.9 %
2011-8.71 %-1,004.88 %-1,208.54 %

Precigen Stock Sales Revenue, EBIT, Earnings per Share

The Precigen earnings per share therefore indicates how much revenue Precigen has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Precigen earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Precigen's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Precigen’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Precigen's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Precigen Revenue, EBIT and net profit per share

DatePrecigen Sales per SharePrecigen EBIT per sharePrecigen Earnings per Share
2030e2.31 undefined0 undefined0.81 undefined
2029e1.95 undefined0 undefined0.77 undefined
2028e1.55 undefined0 undefined0.61 undefined
2027e1.05 undefined0 undefined0.3 undefined
2026e0.41 undefined0 undefined-0.72 undefined
2025e0.05 undefined0 undefined-0.41 undefined
20240.01 undefined-0.35 undefined-0.47 undefined
20230.03 undefined-0.36 undefined-0.39 undefined
20220.13 undefined-0.37 undefined0.14 undefined
20210.07 undefined-0.46 undefined-0.47 undefined
20200.62 undefined-0.51 undefined-1.02 undefined
20190.59 undefined-0.88 undefined-2.09 undefined
20181.17 undefined-2.85 undefined-3.93 undefined
20171.83 undefined-0.68 undefined-0.98 undefined
20161.62 undefined-1.06 undefined-1.58 undefined
20151.56 undefined-1.32 undefined-0.76 undefined
20140.72 undefined-0.71 undefined-0.82 undefined
20130.58 undefined-1.41 undefined-1.4 undefined
20122.51 undefined-13.67 undefined-18.89 undefined
20111.58 undefined-15.85 undefined-19.06 undefined

Precigen business model

Precigen Inc is a biotechnology company headquartered in Germantown, Maryland, USA. The company was founded in 1991 under the name Human Genome Sciences Inc and became the first company in the industry to unlock genetic genes for drug development. In 2019, the company was renamed Precigen Inc. The company specializes in the development of cell and gene therapy products based on the latest advances in regenerative medicine. The goal is to treat diseases that have been difficult or even considered incurable through gene therapy, genome sequencing, and artificial intelligence. Precigen is divided into several divisions: Precigen ActoBio, Precigen Genome, Precigen RegenX, and Precigen Triple Gem. The divisions differ in product development and target application areas. Precigen ActoBio focuses on the development of biological therapies for autoimmune diseases. The company is working on an oral immunotherapy that can treat respiratory and inflammatory bowel diseases. The product is in the testing phase and if all goes well, approval could be within reach. Precigen Genome specializes in genome sequencing. The data from the genes is decoded to develop better medical diagnoses and therapies. Precigen Genome's services range from sequencing genomic information to uncovering further details to interpreting genome data. Precigen RegenX develops gene therapy products for the treatment of rare but severe genetic diseases. The aim is to modify specific genes in the body to achieve a cure or alleviate symptoms. An example of a product from Precigen RegenX is a gene therapy for hemophilia. This product is being tested in phase II clinical trials and could represent a true revolution in treatment. Precigen Triple Gem is the company's newest division, founded in 2020. It is a research and development project focused on novel cancer therapies. The main focus is on the development of CAR-T cells that can recognize and destroy various types of cancer cells. The company has already achieved promising results. The products from Precigen aim to simplify the treatment of severe diseases and minimize side effects through integration into molecular medicine. Patient safety is the top priority. To ensure this, strict testing phases are undergone and there is close monitoring of product development. Precigen's business strategy is based on collaboration with other companies and institutions. The company works with large pharmaceutical companies to support production, distribution, and marketing of the products, among other partnerships. Another important partnership is with universities and research institutions, which help the company in developing new technologies, improving production processes, and conducting clinical trials. This collaboration leads to faster research insights and a larger pool of knowledge and know-how. Precigen is also committed to recruiting the best talent and qualified personnel in the field of biotechnology. Overall, Precigen is an extremely innovative and promising company in the field of regenerative medicine and gene therapy. The company relies on a clever business strategy and forward-thinking partnerships to develop even better therapies for serious, previously incurable diseases in the future. Precigen is one of the most popular companies on Eulerpool.com.

Precigen SWOT Analysis

Strengths

Precigen Inc. has a strong reputation and a well-established presence in the biotechnology industry. The company possesses advanced technological capabilities and a diverse portfolio of innovative products and services. Precigen Inc. has a team of highly skilled professionals who contribute to its success. Moreover, the company has a robust financial position, providing stability and the ability to invest in research and development.

Weaknesses

One of the weaknesses of Precigen Inc. is its dependency on few key customers. This creates a risk of revenue concentration and potential financial impact if any of these customers reduce or discontinue their business with the company. Additionally, Precigen Inc. may face challenges in scaling up its operations and managing growth, which can hinder its ability to effectively meet market demand.

Opportunities

The biotechnology industry is constantly evolving, presenting numerous opportunities for Precigen Inc. to expand its product offerings and diversify its revenue streams. The increasing demand for advanced genetic engineering and gene editing technologies opens up new avenues for the company. Precigen Inc. can also benefit from strategic collaborations and partnerships to leverage complementary expertise and gain access to new markets.

Threats

Precigen Inc. operates in a highly competitive industry, facing threats from both established players and emerging companies. Rapid technological advancements, regulatory changes, and intellectual property disputes pose risks to the company's market position and profitability. External factors, such as economic downturns or geopolitical uncertainties, can impact customer spending and overall demand for biotechnology products.

Precigen Revenue by Segment

  • 3 years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Precigen Revenue by Segment

Segmente2021202020192018
Service revenues75.57 M USD56.9 M USD--
Product revenues27.3 M USD24.35 M USD--
Other revenues502,000 USD722,000 USD--

  • 3 years

  • 5 years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Precigen Revenue by Segment

Segmente2021202020192018
Collaborations and licenses---60.24 M USD
Collaboration and licensing agreements--11.88 M USD-

  • 3 years

  • 5 years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Precigen Revenue by Segment

Segmente2021202020192018
Service--51.8 M USD52.42 M USD
Product--23.78 M USD28.53 M USD
Other--1.08 M USD2.76 M USD

Precigen Revenue by Region

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Precigen Revenue by Segment

DateForeign Countries
201717.61 M USD
201611.97 M USD
20155.92 M USD
20142.17 M USD
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Precigen Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Precigen historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Precigen shares outstanding

The number of shares was Precigen in 2024 — This indicates how many shares 267.727 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Precigen earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Precigen's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Precigen’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Precigen's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Precigen.

Precigen latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2025-0.08 -0.09  (-6.76 %)2025 Q2
3/31/2025-0.08 -0.07  (14.22 %)2025 Q1
12/31/2024-0.06 -0.06  (-3.99 %)2024 Q4
9/30/2024-0.08 -0.09  (-10.29 %)2024 Q3
6/30/2024-0.1 -0.1  (-1.73 %)2024 Q2
3/31/2024-0.09 -0.1  (-11.86 %)2024 Q1
12/31/2023-0.08 -0.13  (-64.35 %)2023 Q4
9/30/2023-0.08 -0.08  (-0.5 %)2023 Q3
6/30/2023-0.1 -0.08  (21.57 %)2023 Q2
3/31/2023-0.09 -0.1  (-7.41 %)2023 Q1
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the Precigen stock

Eulerpool World ESG Rating (EESG©)

42/ 100

🌱 Environment

48

👫 Social

19

🏛️ Governance

59

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Precigen shareholders

%
Name
Stocks
Change
Date
43.45359 % Third Security, LLC116,337,175-507,1823/31/2025
7.71201 % Merck Serono SA20,647,15203/31/2025
6.07661 % Patient Capital Management, LLC16,268,741-1,103,5606/30/2025
4.21175 % Adage Capital Management, L.P.11,276,00006/30/2025
3.67183 % BlackRock Institutional Trust Company, N.A.9,830,493271,4456/30/2025
3.38779 % The Vanguard Group, Inc.9,070,029274,0706/30/2025
1.59814 % Iridian Asset Management LLC4,278,662-307,1476/30/2025
1.40037 % Geode Capital Management, L.L.C.3,749,182269,5806/30/2025
1.23895 % Sabzevari (Helen)3,317,022557,9135/16/2025
1.13141 % State Street Global Advisors (US)3,029,100-9,0276/30/2025
1
2
3
4
5
...
10

Precigen Executives and Management Board

Dr. Helen Sabzevari

(62)
Precigen President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc. (since 2017)
Compensation 3.72 M

Mr. Harry Thomasian

(62)
Precigen Chief Financial Officer
Compensation 1.13 M

Mr. Donald Lehr

(49)
Precigen Chief Legal Officer, Corporate Secretary
Compensation 1.06 M

Mr. Rutul Shah

(43)
Precigen Chief Operating Officer
Compensation 1.04 M

Mr. Jeffrey Perez

(52)
Precigen Senior Vice President - Intellectual Property Affairs
Compensation 872,085
1
2
3

Most common questions regarding Precigen

What values and corporate philosophy does Precigen represent?

Precigen Inc represents a strong commitment to innovation, integrity, and social responsibility. As a leading biotechnology company, Precigen pioneers advancements in the field of genetic research. With a dedicated focus on developing therapies and solutions for human health, they prioritize scientific excellence and cutting-edge technology. Led by a team of experts, Precigen emphasizes collaboration and strategic partnerships to achieve their mission of transforming lives through innovative healthcare solutions. Through their dedication to improving global health outcomes and their unwavering dedication to their core values, Precigen Inc stands as a trusted name in the biotech industry.

In which countries and regions is Precigen primarily present?

Precigen Inc is primarily present in the United States and has its headquarters in Germantown, Maryland.

What significant milestones has the company Precigen achieved?

Precigen Inc, formerly known as Intrexon Corporation, has achieved several noteworthy milestones throughout its history. The company, a leader in synthetic biology, has successfully developed and commercialized various advanced technologies and solutions. Precigen Inc has made significant breakthroughs in the areas of gene and cell therapy, as well as synthetic gene technologies. These accomplishments include the successful clinical trials of their CAR-T therapy candidates, the development of their UltraVector® platform, and the creation of novel genetically modified organisms. Precigen Inc's continuous dedication to innovation and cutting-edge science has positioned them as one of the prominent players in the field.

What is the history and background of the company Precigen?

Precigen Inc, formerly known as Intrexon Corporation, is a biotechnology company based in Germantown, Maryland. Established in 1998, Precigen focuses on applying synthetic biology to solve complex problems across various industries. The company is driven by a mission to create biologically-based solutions to improve the quality of life and promote sustainability. Precigen has expertise in the development and commercialization of advanced gene and cellular therapies, as well as agricultural biotech solutions. With its innovative approach and cutting-edge technologies, Precigen has established itself as a leader in the field of synthetic biology, continuously striving to push boundaries and make a positive impact on the world.

Who are the main competitors of Precigen in the market?

The main competitors of Precigen Inc in the market include companies like Intrexon Corporation, Editas Medicine, CRISPR Therapeutics, and Sangamo Therapeutics.

In which industries is Precigen primarily active?

Precigen Inc is primarily active in the biotechnology industry. As a leading biotech company, Precigen focuses on developing advanced gene and cell therapies, genetic medicines, and agricultural biotechnology solutions. The company harnesses the power of innovative gene editing platforms to address significant unmet needs in healthcare and food production sectors. Precigen Inc leverages its cutting-edge technologies and extensive expertise to create transformative solutions for various genetic disorders, chronic diseases, and sustainable agriculture practices. With its commitment to innovation and scientific progress, Precigen Inc continues to play a vital role in shaping the biotechnology landscape.

What is the business model of Precigen?

Precigen Inc is a biotechnology company focused on utilizing its proprietary synthetic biology technology to develop innovative solutions to global challenges. The business model of Precigen revolves around leveraging its expertise in gene and cell therapy, as well as its advanced bioinformatics capabilities, to address critical needs in healthcare, agriculture, and environmental conservation. With a strong emphasis on precision medicine, the company aims to develop personalized therapies and genetic engineering solutions. Precigen Inc collaborates with various partners to accelerate the development and commercialization of its products and services, aiming to make a positive impact on society through cutting-edge biotechnology advancements.

What is the P/E ratio of Precigen 2025?

The P/E ratio cannot be calculated for Precigen at the moment.

What is the P/S ratio of Precigen 2025?

The P/S cannot be calculated for Precigen currently.

What is the Quality Investing of Precigen?

The Quality Investing for Precigen is 3/10.

What is the revenue of Precigen 2025?

The expected Precigen revenue is 13.7 M USD.

How high is the profit of Precigen 2025?

The expected Precigen profit is -109.23 M USD.

What is the business model of Precigen

Precigen Inc, founded in 2000, is a biotechnology company headquartered in Germantown, Maryland. The company specializes in the development and application of gene editing technologies used in the therapy of severe diseases and genetic disorders. Precigen's business model is based on four main areas: therapeutic product development, agricultural biotechnology, industrial biotechnology, and research and development of genomic technology. Precigen develops therapeutics aimed at curing or alleviating serious diseases such as cancer and genetic disorders using its proprietary gene editing technology platforms like UltraPrecise, ActoBiotics, and X-Press. The company also works in agricultural biotechnology to develop innovative solutions for improving agricultural yields and promoting sustainable farming. In industrial biotechnology, Precigen leverages its expertise to contribute to the development of renewable energy and biofuels. The company explores and develops new technologies in genomics for diagnostic, therapeutic, and disease prevention purposes. Precigen emphasizes the ethical and social aspects of genetic research. Additionally, the company offers products and services based on its technology platforms, such as UltraVector, a proprietary vector design tool that supports DNA construction and gene editing processes. Precigen also holds a license for obtaining plasmid DNA, which helps reduce costs in the production of therapeutics or biotherapeutics. Overall, Precigen has developed a wide range of technologies and applications to assist customers in overcoming complex challenges in various fields, with a focus on gene editing technology and its applications in therapy, agriculture, industrial biotechnology, and genomic research.

What is the Precigen dividend?

Precigen pays a dividend of 0 USD distributed over payouts per year.

How often does Precigen pay dividends?

The dividend cannot currently be calculated for Precigen or the company does not pay out a dividend.

What is the Precigen ISIN?

The ISIN of Precigen is US74017N1054.

What is the Precigen WKN?

The WKN of Precigen is A2PZG1.

What is the Precigen ticker?

The ticker of Precigen is PGEN.

How much dividend does Precigen pay?

Over the past 12 months, Precigen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Precigen is expected to pay a dividend of 0 USD.

What is the dividend yield of Precigen?

The current dividend yield of Precigen is .

When does Precigen pay dividends?

Precigen pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Precigen?

Precigen paid dividends every year for the past 0 years.

What is the dividend of Precigen?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Precigen located?

Precigen is assigned to the 'Health' sector.

Wann musste ich die Aktien von Precigen kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Precigen from 10/7/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/7/2025.

When did Precigen pay the last dividend?

The last dividend was paid out on 10/7/2025.

What was the dividend of Precigen in the year 2024?

In the year 2024, Precigen distributed 0 USD as dividends.

In which currency does Precigen pay out the dividend?

The dividends of Precigen are distributed in USD.

All fundamentals about Precigen

Our stock analysis for Precigen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Precigen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.